Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 5/20 | 0.43 |
| ▸ | CTSE | P14091 | 5/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 5/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22457752 | 0.97 | KLK5 (0.47) | KLK5CTSDCTSEBACE1ACE | |
| SCHEMBL22457522 | 0.89 | ACE (0.51) | ACECMA1 | |
| SCHEMBL24435887 | 0.86 | ACE (0.50) | KLK5CTSDCTSEBACE1ACE | |
| SCHEMBL22457757 | 0.86 | ACE (0.55) | ACECMA1 | |
| SCHEMBL6438312 | 0.86 | ACE (0.55) | ACECMA1 | |
| SCHEMBL7377534 | 0.83 | LTA4H (0.52) | ACECMA1 | |
| SCHEMBL22457742 | 0.79 | REN (0.40) | — | |
| SCHEMBL1401501 | 0.78 | ACE (0.42) | KLK5ACETACR1CMA1 | |
| SCHEMBL28510341 | 0.77 | ACE (0.58) | ACE | |
| SCHEMBL28510337 | 0.77 | ACE (0.58) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| WO-2020189621-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | 日産化学株式会社 | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | KLK5 1276/4885CTSD 858/4885CTSE 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.